Mina, R., Touzeau, C., Hungria, V., Landgren, C. O., Bhutani, D., Chen, W., Kumar, S., Chaulagain, C. P., Dimopoulos, M. A., Bahlis, N. J. J., Maral, S., Donk, N. W. V. D., Saja, K., Teipel, R., Ando, M., Wang, D., Wroblewski, S., Shah, P., Chastain, K., Quach, H. (2026). MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.7507